Determinants of Tacrolimus Interpatient Variability in Renal Transplantation: A Comprehensive Pharmacogenomic and Clinical Review

Tacrolimus is a cornerstone immunosuppressive agent widely used in renal transplantation to prevent graft rejection. Its therapeutic application is challenged by a narrow therapeutic index and substantial interpatient variability in pharmacokinetics and pharmacodynamics. This variability can result in subtherapeutic exposure leading to acute rejection or supratherapeutic levels associated with nephrotoxicity and other adverse effects. The present review provides a comprehensive and critically synthesized evaluation of the determinants contributing to tacrolimus interpatient variability among kidney transplant recipients. Particular emphasis is placed on pharmacogenomic factors, especially polymorphisms in CYP3A5, which significantly influence tacrolimus metabolism and dose requirements. Additionally, drug transporters such as ABCB1 and other genetic variants are explored for their contributory roles. This review shows the impact of drug-drug interactions, formulation variability, adherence patterns, and environmental factors such as diet and lifestyle and importance of therapeutic drug monitoring in mitigating variability and improving clinical outcomes is emphasized. Emerging precision medicine approaches integrating pharmacogenomics with clinical decision-making are critically examined. This review underscores the necessity of a multifactorial and individualized approach to tacrolimus dosing. By integrating genetic, clinical, and environmental determinants, clinicians can enhance therapeutic efficacy, minimize toxicity, and improve long-term graft survival. Future perspectives include the incorporation of artificial intelligence and predictive modeling to optimize personalized immunosuppressive therapy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24424408
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Determinants of Tacrolimus Interpatient Variability in Renal Transplantation: A Comprehensive Pharmacogenomic and Clinical Review

Shaiju S Dharan, Grace N. Raju, Iswarya Chandran
Zenodo (CERN European Organization for Nuclear Research)
Renal Transplantation Outcomes and Treatments
article

Determinants of Tacrolimus Interpatient Variability in Renal Transplantation: A Comprehensive Pharmacogenomic and Clinical Review

Shaiju S Dharan, Grace N. Raju, Iswarya Chandran
article en

Abstract

Tacrolimus is a cornerstone immunosuppressive agent widely used in renal transplantation to prevent graft rejection. Its therapeutic application is challenged by a narrow therapeutic index and substantial interpatient variability in pharmacokinetics and pharmacodynamics. This variability can result in subtherapeutic exposure leading to acute rejection or supratherapeutic levels associated with nephrotoxicity and other adverse effects. The present review provides a comprehensive and critically synthesized evaluation of the determinants contributing to tacrolimus interpatient variability among kidney transplant recipients. Particular emphasis is placed on pharmacogenomic factors, especially polymorphisms in CYP3A5, which significantly influence tacrolimus metabolism and dose requirements. Additionally, drug transporters such as ABCB1 and other genetic variants are explored for their contributory roles. This review shows the impact of drug-drug interactions, formulation variability, adherence patterns, and environmental factors such as diet and lifestyle and importance of therapeutic drug monitoring in mitigating variability and improving clinical outcomes is emphasized. Emerging precision medicine approaches integrating pharmacogenomics with clinical decision-making are critically examined. This review underscores the necessity of a multifactorial and individualized approach to tacrolimus dosing. By integrating genetic, clinical, and environmental determinants, clinicians can enhance therapeutic efficacy, minimize toxicity, and improve long-term graft survival. Future perspectives include the incorporation of artificial intelligence and predictive modeling to optimize personalized immunosuppressive therapy.

Zenodo (CERN European Organization for Nuclear Research)
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Determinants of Tacrolimus Interpatient Variability in Renal Transplantation: A Comprehensive Pharmacogenomic and Clinical Review — Shaiju S Dharan, Grace N. Raju, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS